Impact of multiple switching on health care costs and outcomes in generic drug policies: The Hungarian case of losartan

Z. Kaló, Zsolt Abonyi-Tóth, György Rokszin, Tamás Ágh, András Inotai

Research output: Contribution to journalArticle

Abstract

The objective of this study was to estimate the impact of multiple switching of generic antihypertensive therapy on health outcomes and total health expenditure in a retrospective analysis of payer's database. We included patients with hypertension from the National Health Insurance Fund database into our analysis who were treated with losartan or losartan/hydrochlorothiazide (HCT) in 12-month prior to patent expiry of losartan or losartan/HCT. We compared 3-year MACEs (major cardiovascular events, including stroke, myocardial infarct or death) and treatment costs (antihypertensive drugs, other cardiovascular drugs, cardiovascular treatments, non-cardiovascular interventions) from payer's perspective of those patients with multiple switching of generic drug therapy in 12-month after patent expiry (n = 3.280) with those patients who had been switched to a generic losartan or losartan/HCT brand after patent expiry (single switch) without any additional switching in 12-month (N = 3.101). 9.8% of patients with single switch had MACEs over 36-month compared to 10.7% of patients in the multiple switch group (p = 0.247). Compared to baseline year the difference in total annual treatment costs were higher by € 461 in the multiple switch group than in the single switch group (p < 0.001). Further studies are needed to strengthen the evidence on the suboptimal consequences of multiple switching of generic drugs on health outcomes and total treatment costs compared to single switch.

Original languageEnglish
Pages (from-to)1295-1300
Number of pages6
JournalActa Poloniae Pharmaceutica - Drug Research
Volume74
Issue number4
Publication statusPublished - Jan 1 2017

Keywords

  • Adherence
  • Generic drug policy
  • Health outcomes
  • Losartan
  • Price erosion
  • Switching

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Impact of multiple switching on health care costs and outcomes in generic drug policies: The Hungarian case of losartan'. Together they form a unique fingerprint.

  • Cite this